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httpcense.Abstract Introduction: Delay in diagnosis of paucibacillary extra pulmonary tuberculosis (TB)
and of smear negative TB has hampered the efforts taken by Control Programs to curb its spread.
Better efforts to control spread of TB require more accurate and rapid diagnostic test.
Aims: To facilitate early diagnosis of TB directly from clinical specimens, we have standardized
and validated the use of a single tube in-house nested PCR in comparison against culture and com-
posite reference standard (CRS).
Methods: Single tube nested PCR was performed using primers targeting Insertion Sequence (IS)
6110 of Mycobacterium tuberculosis complex. Microbiological techniques includes AFB smear
microscopy, and cultivation on solid egg-based medium (Lo¨wenstein–Jensen [LJ]) and on liquid cul-
ture medium using BACTEC MGIT 960 system, BD Microbiology Systems.
Results: The sensitivity and speciﬁcity of PCR against culture was observed to be 89.7% [95%
CI: 84.1–93.5] and 73.1% [95% CI: 67.4–78.1] respectively and that against CRS criteria was 80.2%
[95% CI: 75.1–84.5] and 97.1% [95% CI: 92.9–98.9] respectively. PCR showed 100% [111/111, 95%
CI: 97–100] sensitivity for smear positive specimens. For smear negative specimens sensitivity and
speciﬁcity of PCR against culture was observed to be 78.4% [69/88, 95% CI: 68.4–86.5] and 77.3%22 24447795; fax: +91 22
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e Egyptian Society of Chest
g by Elsevier
ng by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and Tuberculosis.
://dx.doi.org/10.1016/j.ejcdt.2013.09.014
806 M. Deshmukh et al.[204/264, 95% CI: 71.7–82.2] respectively and that against CRS was 68.1% [124/182, 95% CI: 60.8–
74.8] and 97.1% [165/170, 95% CI: 93.3–99] respectively.
Conclusion: CRS criteria were observed to be better than culture for assessing the diagnostic
accuracy of PCR test.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
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Tuberculosis is globally still a leading cause of mortality. India
contributes the highest number of new cases, accounting for
21% of the global burden [1]. Early diagnosis and identiﬁca-
tion of TB are essential in instituting effective and timely
therapy. Intense efforts are being taken globally to establish
reliable test for rapid and accurate diagnosis of TB which
would further help in initiating early anti-tubercular therapy.
The conventional methods for diagnosing TB includes: (1) acid
fast bacilli (AFB) smear that has low sensitivity and speciﬁcity;
and (2) culture that is time consuming. Because of these
limitations, nucleic acid ampliﬁcation (NAA) tests have
emerged as promising alternatives and polymerase chain
reaction (PCR) is the most widely used test.
Many studies have reported the use of PCR, using both
commercial kits and in-house assays, for rapid detection of
Mycobacterium tuberculosis (MTB) from various clinical
specimens. Meta-analysis studies have reported sensitivity
and speciﬁcity of commercial assays to be 36–100% and
54–100% and of in-house PCR assays to be 9–100% and 5–
100% respectively [2,3]. The high cost of commercial tests
has restricted its use in developing countries.
Hence in the present study we aim to standardize a single-
tube nested PCR using Insertion Sequence (IS) 6110 and
evaluate its utility for the diagnosis of pulmonary and extrapul-
monary TB and also to evaluate its utility against gold standard
culture technique and composite reference standard (CRS).
Materials and methods
Setting
The study was carried in the College of American Pathologist
(CAP) accredited mycobacteriology laboratory at a tertiary
care centre from August 2004 to April 2008.
Patients
The specimens included in the study were 164 biopsies/tissues,
94 pus/abscess/aspirates, 52 body ﬂuids, 27 sputum, 13 bron-
choalveolar lavage (BAL), 60 cerebrospinal ﬂuid (CSF) and
53 urine samples (Fig. 1). Detailed clinical history (past and
family history, treatment history, radiological scans, and his-
tology/cytology) of each patient was taken by an authorized
trained laboratory personnel by telephonic conversation for
correlation of PCR results.
Inclusion/exclusion criteria
The patients were included if they could provide a detailed
clinical history, radiological scans, histology/cytology, etc.and adequate amount of specimens (2 ml for CSF, 5 ml for
any kind of body ﬂuid, 1 · 1 cm2 for tissues) were available
for both culture and PCR tests.Specimen processing
The specimens were equally divided into 2 parts and as-
signed to the molecular technologist in the molecular diag-
nostic laboratory for the PCR test and to the technologist
in the mycobacteriology laboratory for AFB microscopy
(Ziehl–Neelsen [ZN] staining) and culture by both solid med-
ium (egg-based Lo¨wenstein–Jensen [LJ] [4] and liquid med-
ium (BACTEC MGIT [mycobacteria growth indicator
tube] 960 culture; BD Microbiology Systems). Positive cul-
tures were conﬁrmed for Mycobacterium tuberculosis
(MTB) species by p-nitro benzoic acid assay (PNBA)
[4,5].Molecular testing
All specimens were processed as per the Clinical and Labora-
tory Standards Institute guidelines, in the increasing order of
their smear status i.e., clinical specimens with smear negative
status were processed ﬁrst, followed by AFB scanty, 1+,
2+, and 3+. Also specimens from sterile sites were processed
ﬁrst followed by specimens obtained from non-sterile sites. The
specimens were stored in 20 C and processed for molecular
testing on weekly basis.
(i) DNA extraction:
Decontamination using N-acetyl-L-cysteine (NALC)–so-
dium hydroxide (NaOH) method was performed on pulmon-
ary specimens and extrapulmonary specimens like urine, pus,
abscess, and aspirates. Sterile body ﬂuids, CSF and biopsies
were not subjected for decontamination procedure and were
used directly for extraction protocol. Lysozyme buffer
(300 ll; 300 mg lysozyme, 0.1% Trition X-100, 10 mM
Tris, 1 mM EDTA, pH 8.0) was added to the decontami-
nated pellet and incubated at 37 C in a water bath
overnight. DNA was extracted from the lysate using QIA-
amp DNA mini kit (Qiagen) as per the manufacturer’s
instructions.
(ii) PCR ampliﬁcation:
PCR was performed using IS6110 primer sequences [6,7].
The 50 ll ampliﬁcation mixture consisted of 1· Taq
buffer, 4.5 mM MgCl2, 200 lM of each dNTPs, 0.5 ll
Q-solution, 50 pmol of ISF, ISR primers, 10 pmol of INSF
and INSR primers, 20 pmol of HBGF, HBGR primers
and 1U Hotstar Taq polymerase. Table 1 shows the primer
sequences and PCR cycling conditions. The PCR products
were visualized on 3% agarose gel stained with ethidium
bromide.
Table 1 Primers sequences, corresponding product size and PCR conditions.
Gene Primer sequences (5’ – 3’) Product size 
(bp)
PCR cycling 
conditions
Human -
globin
HBGF: TGAACGTGGATGAAGTTGGTGGTG 291 94oC – 15’
94oC – 1’
66oC – 1’
72oC – 1’
94oC – 1’
70oC – 1’
72oC – 1’
72oC – 10’
4oC – Hold
HBGR: 
ACTTTCTTGCCATGAGCCTTCACCTT
IS6110a ISF: CGTGAGGGCATCGAGGTGGC 245
ISR: GCGTAGGCGTCGGTGACAAA
INSF: CTCGTCCAGCGCCGCTTCGG 123
INSR: CCTGCGAGCGTAGGCGTCGG
× 25
× 30
β
a Published primer sequences [8,9].
Figure 1 Flowchart of patients included and analyzed in this study.
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M - 50 bp ladder 
NC - Negative control 
1 - Healthy control (non-infectious CNS infections) 
2 - Healthy control (healthy individual) 
3 - Diseased control (pyogenic meningitis)  
4 - Diseased control (viral encephalitis)  
5 - Diseased control (malignancy)  
PC - Positive control  
Figure 3 Determination of analytical speciﬁcity of PCR in
healthy and diseased controls.
808 M. Deshmukh et al.PCR validation
(i) Determination of analytical sensitivity of PCR:
The analytical sensitivity of nested PCR was evaluated by
preparing McFarland’s dilutions of standard H37Rv strain
ranging from 1 to 106 cfu/mL. To check for interferences from
clinical specimens’ sputum, pus and urine samples obtained
from patients not having signs and symptoms of TB disease
were spiked with serial dilutions of H37Rv strain.
(ii) Determination of analytical speciﬁcity of PCR
The analytical speciﬁcity of PCR was evaluated on healthy
controls and non-TB diseased controls. Healthy controls com-
prised of 10 CSF samples from patients with non-infectious
ﬁndings such as 4 patients had tumour, 5 patients had delayed
milestones and one patient had a road trafﬁc accident.
Additionally sputum specimens were collected from 10
patients without any signs and symptoms of TB.
Amongst 40 non-TB diseased controls 10 patients with
culture-proven pyogenic meningitis, 10 patients with viral
encephalitis and 30 patients with histopathology proven
malignancy were included. Of the 10 patients with pyogenic
meningitis 6 had Streptococcus pneumoniae grown on culture,
1 had Haemophilus inﬂuenza and 3 had detected the presence
of Cryptococcus neoformans.
(iii) Cross reactivity:
Cross-reactivity was evaluated against commonly isolated
Non-Tuberculosis Mycobacteria (NTM) strains such as Myco-
bacterium fortuitum,Mycobacterium intracellulare,Mycobacte-
rium abscessus, Mycobacterium avium, Mycobacterium
chelonae, Mycobacterium kanasaii and Mycobacterium scrofu-
laceum. Cross reactivity was also evaluated using standard
bacterial and fungal ATCC strains such as Staphylococcus aur-
eus (ATCC 25923), Enterobacteriaceae (ATCC 13047), Klebsi-
ella pneumoniae (ATCC 13883), Escherichia coli (ATCC
25922), Proteus vulgaris (ATCC 8427), Pseudomonas aerogin-
osa (ATCC 27853), and Candida albicans (ATCC 10231).
(iv) Reproducibility:    NC            1              2          3                 M
NC – Negative Control 
1 - 103 copies/ml. 
2 –.102 copies/ml. 
3 – 10 copies/ml 
M - pBR322/HaeIII ladder. 
291 bp 
123 bp 
Figure 2 Determination of analytical sensitivity of PCR using
spiked sputum specimens.Sputum specimens from patients not suffering from TB
disease were spiked with 10copies/ml of standard H37RV
strain. Reproducibility was evaluated by performing extraction
and ampliﬁcation on spiked specimens for 10 times within
batch and in between 10 different batches.N1   - PCR Negative control 
N2   - Extraction negative control 
1, 2   - Samples showing inhibition by nested PCR 
4, 5, 9   - Samples negative by nested PCR 
3, 6, 7, 8  - Samples positive by nested PCR 
M   - pBR322/HaeIII ladder 
Figure 4 Nested PCR in different clinical specimens.
Table 2 Positive results of smear, culture, PCR and CRS in different clinical specimens.
Smear positive (%) Culture positive (%) PCR positive (%) CRS positive (%)
CSF (60) 2 (3) 14 (23) 29 (48) 42 (70)
Body ﬂuids (52) 3 (6) 16 (31) 19 (36) 27 (52)
Tissues (164) 44 (27) 60 (37) 77 (47) 91 (55)
Pus (94) 48 (51) 55 (58) 68 (72) 74 (79)
Urine (53) 6 (11) 20 (38) 24 (45) 36 (68)
Total extrapulmonary (423) 103 (22) 165 (39) 217 (51) 270 (64)
Sputum (27) 6 (22) 14 (52) 16 (59) 17 (63)
BAL (13) 2 (15) 5 (38) 7 (54) 6 (46)
Total pulmonary (40) 8 (20) 19 (47) 23 (57) 23 (57)
Total specimens (463) 111 (24) 184 (40) 240 (52) 293 (63)
Table 3 Comparison of smear with culture and CRS in different clinical specimens.
Culture positive (184) Culture negative (279) CRS positive (293) CRS negative (170)
Smear positive (111) 96 15 111 0
Smear negative (352) 88 264 182 170
Table 4 Comparison of culture with CRS in different clinical specimens.
CRS positive CRS negative
CSF Culture positive 14 0
Culture negative 28 18
Body ﬂuids Culture positive 16 0
Culture negative 11 25
Tissues Culture positive 60 0
Culture negative 31 73
Pus Culture positive 55 0
Culture negative 19 20
Urine Culture positive 20 0
Culture negative 16 17
Total extrapulmonary Culture positive 165 0
Culture negative 105 153
Sputum Culture positive 14 0
Culture negative 3 10
BAL Culture positive 5 0
Culture negative 1 7
Total pulmonary Culture positive 19 0
Culture negative 4 17
Total specimens Culture positive 184 0
Culture negative 109 170
Is a composite reference standard (CRS) an alternative to culture in assessment 809(v) Validation of PCR products by sequencing
The PCR products were validated by sending 10 represen-
tative samples for DNA sequencing (Bangalore Genei, Banga-
lore) and the speciﬁcity of the ampliﬁed sequence was
conﬁrmed by performing BLAST analysis.
Quality control measures
Measures to avoid false positive PCR results and to minimize
cross contamination were followed as previously reported
[8,9]. Every batch of PCR mixture included reagent controls
for extraction reagents and PCR reagents, negative controls,
and positive control. The incorporation of b globin gene
PCR served as an internal control to monitor PCR inhibition
in every sample.Patient categorization
Patients were categorized into 4 categories: ‘Conﬁrmed TB’,
‘Probable TB’, ‘Possible TB’ and ‘Not TB’ cases using a CRS
algorithm as described in a study by Vadwai et al. [10]. Con-
ﬁrmed TB cases comprised of smear positive/culture positive
and smear negative/culture positive patients. Probable TB cases
comprised of culture negative patients showing clinical signs/
symptoms of TB, radiological ﬁndings and/or histology/cytol-
ogy are suggestive of TB. Possible TB cases include patients
showing only clinical signs/symptoms of TB whereas all other
tests including culture were negative. In these patients response
to empirical anti-tuberculosis treatment (ATT) was determined
after 3 months. Not TB cases comprised of culture and all other
tests are negative with patient responding to non-TB treatment.
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810 M. Deshmukh et al.Statistical analysis
Diagnostic accuracy of PCR against culture and CRS criteria
was performed using MetaDisc software to calculate sensitiv-
ity, speciﬁcity, predictive values, diagnostic odds ratios, and
likelihood ratios. Wilson’s binomial theorem was used to cal-
culate 95% conﬁdence intervals (CI) [11]. Post test probability
for positive and negative results was calculated using Pre and
post test probability calculator (http://www.mashpedia.com/
Pre-_and_post-test_probability).
Results
PCR validation
Analytical sensitivity of PCR was found to be 10 cfu/ml
(Fig. 2). No cross-reactivity was observed with the standard
bacterial, fungal and NTM strains and also in 20 healthy
and 40 diseased controls (Fig. 3). Reproducibility of nested
PCR in-between and within the batches was observed.
Sequencing and BLAST analysis demonstrated maximum
homology of the ampliﬁed products with MTB complex strains
published in the NCBI database. Different clinical specimens
were then subjected to standardized and validated nested
PCR (Fig. 4).
Patients
A total of 562 patients were screened for the inclusion/exclu-
sion criteria and 466 patients following the criteria were in-
cluded in the study. In the preliminary data analysis 0.64%
(3/466) patients were excluded since culture grew non-tubercu-
losis mycobacterial (NTM). Thus 463 patients were included in
the ﬁnal data analysis. The mean age of the patients was 33
(±21 years, standard deviation) years and the male:female
sex ratio was 1.2:1. None of the patients included in the study
were positive for human immunodeﬁciency virus (HIV).
Of the 463 patients 24% were smear positive, 40% were cul-
ture positive, 52% were PCR positive and 63% were positive
by CRS criteria (Table 2). Of the total specimens 20.73%
(96/463) were positive by both smear and culture, 19% (88/
463) were smear negative/culture positive, 3.24% (15/463)
were smear positive/culture negative and 57.02% (264/463)
were negative by both smear and culture. Of the total
specimens 50.76% (235/463) were positive by both PCR and
CRS criteria and 12.52% (58/463) were positive by CRS crite-
ria only.
AFB smear ﬁndings
AFB smear showed sensitivity and speciﬁcity of 52.2% (95%
CI: 44.7–59.6) and 94.6% (95% CI: 91.3–97) respectively with
culture (Table 3) and 37.9% (95% CI: 32.3–43.7) and 100%
(95% CI: 97.9–100) respectively against CRS criteria.
Culture results
Of the total 463 specimens 39% (182/463) were positive by
MGIT liquid culture and 25% (116/463) showed growth on
conventional LJ media. Of the total 184 culture positive spec-
imens, 37% (68/184) were positive only by MGIT, 1% (2/184)
Table 6 Comparison of PCR results with smear and culture in different clinical specimens.
Total = 463 Smear positive (111) Smear negative (352)
Culture positive (96) Culture negative (15) Culture positive (88) Culture negative (264)
PCR
positive
PCR
negative
PCR
positive
PCR
negative
PCR
positive
PCR
negative
PCR
positive
PCR
negative
CSF (60) 2 0 0 0 8 4 19 27
Body ﬂuids
(52)
3 0 0 0 9 4 7 29
Tissue (164) 37 0 7 0 20 3 13 84
Pus (94) 43 0 5 0 10 2 10 24
Urine (53) 4 0 2 0 11 5 7 24
Extra pul
(423)
89 0 14 0 58 18 56 188
Sputum (27) 5 0 1 0 8 1 2 10
BAL (13) 2 0 0 0 3 0 2 6
Pul (40) 7 0 1 0 11 1 4 16
Total (463) 96 0 15 0 69 19 60 204
Is a composite reference standard (CRS) an alternative to culture in assessment 811was positive only on LJ media and 62% (114/184) were posi-
tive both by MGIT and LJ media.
The comparison of culture results with CRS in different
specimens is given in Table 4. Overall culture showed sensitiv-
ity, speciﬁcity, positive predictive value (PPV) and negative
predictive value (NPV) of 62.8%, 100%, 100% and 60.93%
respectively with CRS (Table 5). The positive likelihood ratio
(PLR), negative likelihood ratio (NLR), post test probability
of positive result and post test probability of negative result
were observed to be 214.62%, 0.37%, 100% and 39%
respectively.Diagnostic accuracy of PCR with culture
Table 6 represents the comparison of PCR results with smear
and culture in different clinical specimens. Amongst smear po-
sitive specimens 86.5% (96/111) were positive by both culture
and PCR and additionally 13.5% were positive only by PCR.
Amongst smear negative specimens 19.6% (69/352) were posi-
tive by both culture and PCR, additionally 17% (60/352) were
positive only by PCR, 5.4% (19/352) were positive by culture
only and 57.9% (204/352) were negative both by culture and
PCR.
The diagnostic accuracy of PCR against culture in different
clinical specimens is depicted in Table 7. Overall sensitivity,
speciﬁcity, PPV and NPV were observed to be 89.7%,
73.1%, 68.75% and 91.48% respectively. The PLR, NLR, post
test probability of positive result, and post test probability of
negative result were observed to be 3.34%, 0.14%, 69% and
8.5% respectively. PCR showed 100% [111/111, 95% CI:
97–100] sensitivity for smear positive specimens. For smear
negative specimens sensitivity and speciﬁcity were observed
to be 78.4% [69/88, 95% CI: 68.4–86.5] and 77.3% [204/264,
95% CI: 71.7–82.2] respectively.
Diagnostic accuracy of PCR with CRS
Table 8 represents the comparison of PCR results with smear
and CRS in different clinical specimens. All smear positive
specimens were positive by both PCR and CRS. Amongst
smear negative specimens 35.27% (124/352) were positive byboth PCR and CRS, 1.4% (5/352) were positive only by
PCR, 16.48% (58/352) were positive by CRS only and
46.87% (165/352) were negative both by culture and PCR.
The diagnostic accuracy of PCR against CRS in different
clinical specimens is depicted in Table 9. Overall PCR showed
sensitivity, speciﬁcity, PPV and NPV of 80.2%, 97.1%,
97.92% and 73.99% respectively. The PLR, NLR, post test
probability of positive result and the post test probability were
27.27, 0.204, 98% and 26% respectively. For smear positive
specimens PCR showed 100% sensitivity with CRS
criteria also. For smear negative specimens sensitivity and
speciﬁcity of PCR against CRS was 68.1% [124/182, 95%
CI: 60.8–74.8] and 97.1% [165/170, 95% CI: 93.3–99]
respectively.
PCR results in different categories of patients
Based on the CRS criteria 42.98% (n= 199/463) patients were
‘Conﬁrmed TB’ cases, 20.3% (n= 94/463) patients were
‘Probable TB’ cases and 36.72% (n= 170/463) patients were
‘Not TB’ cases. None of the patients were classiﬁed as ‘‘Possi-
ble TB’’ cases. Nested PCR was positive in 89% of ‘‘conﬁrmed
TB cases’’ and in 59% of ‘‘probable TB’’ cases (Table 10). In
‘not-TB’ cases 2.94% (5/170) were positive by nested PCR.
Inhibition rate
The inhibitory rate was observed to be 3.4% (16/463) and the
contamination rate of MGIT culture was 1.9% (9/463) and
that of LJ was 3.02% (14/463). The inhibition rates for differ-
ent specimen matrices were observed to be 3.7% (1/27), 3.33%
(2/60), 5.76% (3/52), 1.83% (3/164), 2.13% (2/94) and 9.43%
(5/53) for Sputum, CSF, body ﬂuids, tissues/biopsies, pus/ab-
scess, and urine specimens respectively.
Discussion
Diagnosis of TB relies on the detection of AFB by microscopy
and culture which lack sensitivity and rapidity respectively.
The major dilemma lies in the diagnosis of extrapulmonary
TB due to atypical clinical presentations. Several meta-analysis
Table 7 Statistical analysis of PCR results with smear and lture in different clinical specimens.
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
PL
(95 CI)
NLR
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
Prevalence or
pre test
probability
(95% CI)
Post test
probability
of positive
result (95% CI)
Post test
probability
of negative
result (95% CI)
CSF 71.4 (41.9–91.6) 58.7 (43.2–73) 1.7 (1.07–2.79) 0.49 (0.20–1.15) 34 (19–54) 87 (69–96) 23 (14–36) 34 (25–46) 13 (6–26)
Body ﬂuids 75 (47.6–92.7) 80.6 (64–91.8) 3.8 (1.87–7.94) 0.31 (0.13–0.74) 63.16 (38.63–82.77) 87.88 (70.86–96.04 31 (19–45) 63 (45–78) 12 (5–25)
Tissues 95 (86.1–99) 80.8 (71.9–87.8) 4.9 (3.32–7.36) 0.06 (0.02–0.19) 74.03 (62.57–83.05) 96.55 (89.55–99.11 36.6 (29–44) 74 (66–81) 3 (1–10)
Pus 96.4 (87.5–99.6) 61.5 (44.6–76.6) 2.5 1.68–3.74) 0.06 (0.01–0.24) 77.94 (65.94–86.74) 92.31 (73.4–98.66) 58 (48–68) 78 (70–84) 8 (1–25)
Urine 75 (50.9–91.3) 72.7 (54.5–86.7) 2.7 (1.49–5.07) 0.34 (0.16–0.75) 62.5 (40.76–80.45) 82.76 (63.51–93.47 38 (25–52) 62 (47–75) 17 (9–32)
Total extra pulmonary 89.1 (83.3–93.4) 72.9 (67–78.2) 3.2 (2.67–4.04) 0.15 (0.10–0.23) 67.74 (61.02–73.82) 91.26 (86.33–94.59 39 (34–44) 68 (63–72) 9 (6–13)
Sputum 92.9 (66.1–99.8) 76.9 (46.2–95) 4.0 (1.48–10.97) 0.09 (0.01–0.63) 81.25 (53.69–95.03) 90.91 (57.12–99.52 52 (32–71) 81 (61–92) 9 (1–40)
BAL 100 (47.8–100) 75 (34.9–96.8) 3.3 1.12–9.72) 0.11 (0.01–1.69) 71.43 (30.26–94.89) 71.43 38 (15–68) 71 (41–86) 0 (0–51)
Total pulmonary 94.7 (74–99.9) 76.2 (52.8–91.8) 3.9 (1.84–8.61) 0.07 (0.01–0.47) 78.26 (55.79–91.71) 94.12 (69.24–99.69 47 (32–64) 78 (62–89) 6 (1–30)
Total 89.7 (84.1–93.5) 73.1 (67.4–78.1) 3.3 (2.73–4.07) 0.14 (0.09–0.22) 68.75 (62.41–74.47) 91.48 (86.82–94.66 40 (35–44) 69 (64–73) 8.5 (6–13)
Table 8 Comparison of PCR results with smear and CRS different clinical specimens.
Total = 463 Smear positive (111) Smear negative (352)
CRS positive (111) CRS negative (0) CRS positive (182) CRS negative (170)
PCR positive PCR neg ive PCR positive PCR negative PCR positive PCR egative PCR positive PCR negative
CSF (60) 2 0 0 0 26 14 1 17
Body ﬂuids (52) 3 0 0 0 15 9 1 24
Tissue (164) 44 0 0 0 33 14 0 73
Pus (94) 48 0 0 0 20 6 0 20
Urine (53) 6 0 0 0 17 13 1 16
Extra pul (423) 103 0 0 0 111 56 3 150
Sputum (27) 6 0 0 0 10 1 0 10
BAL (13) 2 0 0 0 3 1 2 5
Pul (40) 8 0 0 0 13 2 2 15
Total (463) 111 0 0 0 124 58 5 165
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Is a composite reference standard (CRS) an alternative to culture in assessment 813studies have reported the diagnostic accuracy of in-house and
commercial NAAT for the diagnosis of pulmonary and extra-
pulmonary TB and have concluded that the accuracy could not
be determined for in-house PCR assays due to heterogeneity
across studies [12]. Hence in this study we have attempted to
determine the diagnostic accuracy of in-house PCR for the
diagnosis of TB focusing mainly on extrapulmonary TB.
Meta-analysis studies have reported that the use of IS6110
target sequence and nested PCR produced higher diagnostic
odds ratio compared to those using other targets and regular
PCR protocols respectively [3,12]. Accordingly in this a study
single tube nested PCR was meticulously standardized by
performing modiﬁcations in the extraction protocol which
included overnight incubation with lysozyme, increasing lysis
time up to 2 h and concentrating DNA by using 75 ll AE
buffer. To the best of our knowledge the combination of outer
and inner primers used in this study to standardize a single
tube nested PCR has not been reported, though these primer
sets have been used separately.
In the present study sensitivity of smear against culture and
CRS was observed to be 52.2% and 37.9% respectively, of
PCR was 89.7% and 80.2% respectively and of culture was
62.8% against CRS. These were greater than those reported
in the previous studies [13,14]. Of the CRS positive patients
37.2% (109/293, Table 4) were culture negative which attrib-
uted to the low sensitivity of culture. Low sensitivity of culture
could be explicated to the fact that 68% (51/75) of culture
negative, and PCR positive/CRS positive patients were
receiving anti-tuberculosis treatment (ATT) for varying
periods of time ranging from 2 to 8 days. Other possible
explanations include paucibacillary nature of extrapulmonary
specimens and loss of viable bacilli during NALC–NaOH
decontamination procedure.
Diagnostic accuracy of PCR
The sensitivity of PCR was observed to be 89.7% and 80.2%
respectively with culture and CRS criteria which were greater
than 83% [14] and 74.2% [13] sensitivity reported in the
previous studies. Speciﬁcity of PCR was observed to be
58.7% and 94.4% respectively with culture and CRS criteria.
Speciﬁcity against CRS criteria was comparable with that of
94.59% [14] and 95% [13] reported in the previous studies.
The speciﬁcity against culture was lower because 59% of pa-
tients with ‘Probable TB’ were positive by PCR and negative
by culture. Hence CRS criteria were observed to be better than
culture in determining the diagnostic accuracy of PCR test. In
smear positive specimens PCR showed sensitivity of 100%
both with culture and CRS criteria which was similar to that
reported [14]. In smear negative specimens PCR showed a sen-
sitivity of 78.4% and 68.1% respectively with culture and CRS
criteria which was greater than that reported.
In the smear negative specimens 58 were CRS positive/PCR
negative (Table 8) of which 19 were culture positive and 39
were culture negative. In the 39 CRS positive patients the
negative results by smear, culture, and PCR indicate either
absence or extremely low mycobacterial load. Of the 19 culture
positive patients, 16 showed PCR inhibition. Though the
inhibition effect was neutralized after repetition of PCR in
all 16 specimens, these samples did not show the presence of
MTB speciﬁc PCR product. Thus the absence of MTB speciﬁc
Table 10 PCR positivity in different categories of patients.
Conﬁrmed TB cases Probable TB cases Not TB cases
CSF 10/14 (71%) 18/28 (64%) 1/18
Body ﬂuids 12/16 (75%) 6/11 (55%) 1/25
Tissues 64/67 (96%) 13/24 (54%) 0/73
Pus 55/60 (92%) 10/14 (71%) 0/20
Urine 17/22 (77%) 6/14 (43%) 1/17
Total extrapulmonary 158/179 (88%) 53/91 (58%) 3/153
Sputum 14/15 (93%) 2/2 (100%) 0/10
BAL 5/5 (100%) 0/1 (0%) 2/7
Total pulmonary 19/20 (95%) 2/3 (67%) 2/17
Total 177/199 (89%) 55/94 (59%) 5/170
814 M. Deshmukh et al.product in all these specimens could be attributed to the extre-
mely paucibacillary nature of these specimens.
Diagnostic accuracy of PCR in pulmonary specimens
Previous studies using IS6110 PCR have reported higher sensi-
tivity in pulmonary specimens (92–99%) than extrapulmonary
specimens (39–91%) [15]. Wide variability in sensitivity and
speciﬁcity ranging from 9.4% to 100% and 5.6% to 100%
respectively for the diagnosis of pulmonary TB using in-house
PCR test was reported [3]. Likewise in the present study the
sensitivity and speciﬁcity of PCR in pulmonary specimens
was observed to be 94.7% and 76.2% respectively against cul-
ture and 91.3% and 88.2% respectively against CRS criteria.
Sensitivity of in-house PCR for smear positive pulmonary
specimens has been reported to be 96% [16] and for smear neg-
ative pulmonary specimens wide variability was reported in
sensitivity (9–100%) and speciﬁcity (25–100%) [17]. In present
study 100% sensitivity was observed for smear positive
pulmonary specimens, and 87% and 92% sensitivity was ob-
served respectively against culture and CRS criteria for smear
negative pulmonary specimens. The speciﬁcity was observed to
be 88% and 80% respectively against culture and CRS.Diagnostic accuracy of PCR in extra pulmonary specimens
Previous studies using IS6110 PCR have reported sensitivity
ranging from 39% to 91% for extrapulmonary specimens [15].
In the present study sensitivity of PCR in extra pulmonary spec-
imens was observed to be 89.1% and 79.3% respectively with
culture and CRS criteria. Wide variability (0–100%) between
sensitivities of in-house PCR tests has been reported for the
diagnosis of TBM [18]. In the present study sensitivity of PCR
from CSF specimens was observed to be 71.4% with culture
and 66.7% with CRS. Similarly wide variability in sensitivity
(20–100%) and speciﬁcity (53–100%) has been reported be-
tween in-house PCR assays for the diagnosis of TB pleuritis
[12]. Present study showed sensitivity and speciﬁcity of 75%
and 80.6% respectively with culture and 66.7%and 96% respec-
tively with CRS criteria for detection of MTB from body ﬂuids.
High sensitivity and speciﬁcity for tissues/biopsies speci-
mens against both culture and CRS were observed in the pres-
ent study. Sensitivity of 74.07–87.5% has been reported for
various tissues specimens [19–23]. In the present study a very
high sensitivity of >90% was observed for aspirates/pus/
abscess specimens against both culture and CRS criteria which
is greater than the reported sensitivity of 69.2% [22].PCR showed sensitivity of 75% and 63.9% against culture
and CRS criteria respectively for urine specimens which are
comparable to that reported [22].
Different groups
With CRS criteria, nested PCR assay showed good overall sen-
sitivity of 89% (177/199) in conﬁrmed-TB cases (Table 10).
Nested PCR showed sensitivity of 59% (55/94) in probable-
TB cases who had strong clinical indications of TB (had
positive radiological tests and/or positive histology/cytology
reports, while some of the patients were already on antituber-
cular treatment at the point of enrolment in the study).
Inhibition rate and false positive rate
In the present study the overall inhibition rate of nested PCR
was observed to be 3.4% which was lower than the reported
rate of 4.8% [19] and 12.5% [24].
The false positive rate of nested PCR was observed to be
very low 2.9% (5/170; 95% CI: 1–7) than that reported in
the earlier study [25]. Several precautions were followed to
minimize cross contamination: (1) Nested PCR was standard-
ized in a single tube to prevent cross contamination; (2) re-
agent control was included in every batch to monitor cross
contamination; (3) big batches of specimen processing were
avoided; and (4) specimens were processed according to CLSI
guidelines in increasing order of smear status.
Likelihood ratios and Post test probability of PCR
The PLR and NLR in total specimens when compared with
culture were 3.34 and 0.14 respectively. With CRS criteria
enhancement in likelihood ratios was observed. The high
PLR (27.27) and very low NLR (0.204) indicate good proba-
bility for ‘ruling in’ and ‘ruling out’ disease respectively. If
PCR test was positive, the likelihood that this patient has
TB increases from 63% (pre-test probability) to 98%, a prob-
ability that is sufﬁciently high to justify initiation of anti-tuber-
culosis treatment (ATT). The post test probability was higher
with CRS criteria (98%) than culture (69%) in ‘ruling in’ TB
disease. Likewise if the PCR result was negative, the probabil-
ity of TB disease was reduced to 26%. Different clinical
specimens showed high post test probability for positive result
which would deﬁnitely help in initiation of early ATT particu-
larly in paucibacillary extrapulmonary TB cases. However in
extrapulmonary specimens the post test probability for
negative result was not sufﬁciently low to rule out TB with cer-
Is a composite reference standard (CRS) an alternative to culture in assessment 815tainty. This could be attributed to the paucibacillary nature of
specimens obtain from the extra pulmonary sites. Overall the
likelihood ratios and the post test probability were observed
to be greater with CRS criteria than those with culture. This
highlights the usefulness of CRS criteria for determining the
diagnostic accuracy of highly sensitive PCR test.
Strength and limitation of the study
Strength of the study includes: (1) large number of extra pul-
monary specimens were analyzed for smear, culture and PCR
tests; (2) evaluation of PCR against CRS criteria showed better
diagnostic accuracy of the test; and (3) post test probability
gave better understanding of clinical utility of the PCR test as
a diagnostic tool especially for extra pulmonary TB. The lack
of incorporation of uracil N-glycosylase (UNG) could be con-
sidered as a limitation of this PCR assay. However we have
attempted to address this issue of carry-over contamination
by standardizing the nested PCR in a single tube, thereby pre-
cluding transfer of ampliﬁed products for the nested reaction.
We conclude that CRS criteria were better than culture for
assessing the diagnostic accuracy of PCR test and that PCR
showed good clinical utility for ‘ruling in’ TB with certainty
in extra pulmonary specimens.Acknowledgements
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